Tumor response parameters for head and neck cancer derived from tumor-volume variation during radiation therapy

2013 ◽  
Vol 40 (3) ◽  
pp. 034101 ◽  
Author(s):  
Alexei V. Chvetsov
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Volume ◽  
Tumor Response ◽  
Volume Variation

Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy

2010 ◽  
Vol 49 (2) ◽  
pp. 201-208 ◽  
Author(s):  
Young Mi Seol ◽  
Bo Ran Kwon ◽  
Moo Kon Song ◽  
Young Jin Choi ◽  
Ho Jin Shin ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Volume

scholarly journals Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Therapy Oncology Group 8502 “QUAD shot” regimen for incurable head and neck cancer

2020 ◽  
Author(s):  
Ryo Toya ◽  
Tetsuo Saito ◽  
Kohsei Yamaguchi ◽  
Tomohiko Matsuyama ◽  
Takahiro Watakabe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Response ◽  
Symptom Relief ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group ◽  
Overall Response ◽  
Volumetric Modulated Arc Radiotherapy

Abstract Background: To review a single institutional experience of the Radiation Therapy Oncology Group (RTOG) 8502 “QUAD shot” regimen using volumetric modulated arc radiotherapy (VMAT) for incurable head and neck cancer (HNC).Methods: Thirty-four consecutive patients with HNC were treated with at least one cycle of the RTOG 8502 regimen. Treatment plans included the use of VMAT with 6 MV photons generated by a linear accelerator. Two daily fractions of 3.7 Gy were delivered with an interval of at least 6 h for 2 consecutive days, totaling 14.8 Gy over 4 fractions. This was repeated every 3–4 weeks for a total of three cycles. No concurrent systemic therapy was performed.Results: The number of completed cycles was 1 in 6 (18%) patients, 2 in 5 (15%), and 3 in 23 (68%). Tumor response was achieved in 29 (85%) patients and symptom relief in 20 (77%) of 26 patients. Overall response (tumor response or symptom relief) was achieved in 32 (94%) patients. All patients who received 2 or more treatment cycles achieved overall response. Median overall survival (OS) was 5.7 months. Multivariate analysis revealed that completion of all three treatment cycles was significantly associated with better OS (P = 0.002). Grade 2 toxicity was observed in four (12%) patients, but no acute Grade ≥3 or late toxicity was observed.Conclusions: The RTOG 8502 “QUAD shot” regimen using VMAT is effective for incurable HNC with highly reduced toxicity. Treatment with multiple cycles is recommended for better treatment response and/or survival.

scholarly journals Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Therapy Oncology Group 8502 “QUAD shot” regimen for incurable head and neck cancer

2020 ◽  
Author(s):  
Ryo Toya ◽  
Tetsuo Saito ◽  
Kohsei Yamaguchi ◽  
Tomohiko Matsuyama ◽  
Takahiro Watakabe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Response ◽  
Symptom Relief ◽  
Radiation Therapy Oncology Group ◽  
Oncology Group ◽  
Overall Response ◽  
Volumetric Modulated Arc Radiotherapy

Abstract Background : To review a single institutional experience of the Radiation Therapy Oncology Group (RTOG) 8502 “QUAD shot” regimen using volumetric modulated arc radiotherapy (VMAT) for incurable head and neck cancer (HNC). Methods : Thirty-four consecutive patients with HNC were treated with at least 1 cycle of the RTOG 8502 regimen. Treatment plans included the use of VMAT with 6 MV photons generated by a linear accelerator. Two daily fractions of 3.7 Gy were delivered with an interval of at least 6 h for 2 consecutive days, totaling 14.8 Gy over 4 fractions. This was repeated every 3–4 weeks for a total of 3 cycles. No concurrent systemic therapy was performed. Results : The number of completed cycles was 1 in 6 (18%) patients, 2 in 5 (15%), and 3 in 23 (68%). Tumor response was achieved in 29 (85%) patients and symptom relief in 20 (77%) of 26 patients. Overall response (tumor response or symptom relief) was achieved in 32 (94%) patients. All patients who received 2 or more treatment cycles achieved overall response. Median overall survival (OS) was 5.7 months. Multivariate analysis revealed that completion of all 3 treatment cycles was significantly associated with better OS ( P = 0.002). Grade 2 toxicity was observed in 4 (12%) patients, but no acute or late toxicities of Grade ≥3 were observed. Conclusions : The RTOG 8502 “QUAD shot” regimen using VMAT is effective for incurable HNC with highly reduced toxicities. Treatment with multiple cycles is recommended for better treatment response and/or survival.

Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer

1998 ◽  
Vol 47 (2) ◽  
pp. 175-183 ◽  
Author(s):  
Gerhard G Grabenbauer ◽  
Helmuth Steininger ◽  
Martin Meyer ◽  
Rainer Fietkau ◽  
Thomas Brunner ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Prognostic Factors ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Volume ◽  
Stage Iii ◽  
Total Tumor Volume ◽  
Ct Density

scholarly journals Acute Toxicity and Preliminary Clinical Outcomes of Concurrent Radiation Therapy and Weekly Docetaxel and Daily Cisplatin for Head and Neck Cancer

2005 ◽  
Vol 35 (11) ◽  
pp. 639-644 ◽  
Author(s):  
Yoshizumi Kitamoto ◽  
Tetsuo Akimoto ◽  
Hitoshi Ishikawa ◽  
Tetsuo Nonaka ◽  
Hiroyuki Katoh ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Acute Toxicity ◽  
Head And Neck ◽  
Clinical Outcomes ◽  
Neck Cancer ◽  
Weekly Docetaxel
Sign in / Sign up

Export Citation Format

Share Document